Skip to main content
Erschienen in:

28.05.2024 | REVIEW

Exploring the Interplay between Diabetes and Lp(a): Implications for Cardiovascular Risk

verfasst von: Corral Pablo, Arrupe Matías, Augusto Lavalle Cobo, Gimenez Sergio, Renna Nicolás Federico

Erschienen in: Current Diabetes Reports | Ausgabe 7/2024

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

The objective of this manuscript is to review and describe the relationship between Lp(a) and diabetes, exploring both their association and synergy as cardiovascular risk factors, while also describing the current evidence regarding the potential connection between low levels of Lp(a) and the presence of diabetes.

Recent Findings

Epidemiological studies suggest a potential relationship between low to very low levels of Lp(a) and diabetes.

Summary

Lipoprotein(a), or Lp(a), is an intriguing lipoprotein of genetic origin, yet its biological function remains unknown. Elevated levels of Lp(a) are associated with an increased risk of cardiovascular atherosclerosis, and coexisting diabetes status confers an even higher risk. On the other hand, epidemiological and genetic studies have paradoxically suggested a potential relationship between low to very low levels of Lp(a) and diabetes. While new pharmacological strategies are being developed to reduce Lp(a) levels, the dual aspects of this lipoprotein's behavior need to be elucidated in the near future
Literatur
1.
Zurück zum Zitat Kronenberg F, Mora S, Stroes ESG, Ference BA, Arsenault BJ, Berglund L, Dweck MR, Koschinsky M, Lambert G, Mach F, McNeal CJ, Moriarty PM, Natarajan P, Nordestgaard BG, Parhofer KG, Virani SS, von Eckardstein A, Watts GF, Stock JK, Ray KK, Tokgözoğlu LS, Catapano AL. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J. 2022;43(39):3925–46. https://doi.org/10.1093/eurheartj/ehac361.CrossRefPubMedPubMedCentral Kronenberg F, Mora S, Stroes ESG, Ference BA, Arsenault BJ, Berglund L, Dweck MR, Koschinsky M, Lambert G, Mach F, McNeal CJ, Moriarty PM, Natarajan P, Nordestgaard BG, Parhofer KG, Virani SS, von Eckardstein A, Watts GF, Stock JK, Ray KK, Tokgözoğlu LS, Catapano AL. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J. 2022;43(39):3925–46. https://​doi.​org/​10.​1093/​eurheartj/​ehac361.CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat •• Lamina C, Ward NC. Lipoprotein (a) and diabetes mellitus. Atherosclerosis. 2022 ;349:63–71. https://doi.org/10.1016/j.atherosclerosis.2022.04.016. (This review aims to shed light on the most recent findings of epidemiological and Mendelian Randomisation studies regarding the inverse association between Lp(a) and risk of prevalent and incident diabetes.) •• Lamina C, Ward NC. Lipoprotein (a) and diabetes mellitus. Atherosclerosis. 2022 ;349:63–71. https://​doi.​org/​10.​1016/​j.​atherosclerosis.​2022.​04.​016. (This review aims to shed light on the most recent findings of epidemiological and Mendelian Randomisation studies regarding the inverse association between Lp(a) and risk of prevalent and incident diabetes.)
13.
Zurück zum Zitat •• Kronenberg F. Lipoprotein(a): from Causality to Treatment. Curr Atheroscler Rep. 2024;26(3):75–82. https://doi.org/10.1007/s11883-024-01187-6 (This paper reviews the evidence why lipoprotein(a) (Lp(a)) is a causal risk factor for cardiovascular disease and how high Lp(a) concentrations should be managed now and with an outlook to the future.) •• Kronenberg F. Lipoprotein(a): from Causality to Treatment. Curr Atheroscler Rep. 2024;26(3):75–82. https://​doi.​org/​10.​1007/​s11883-024-01187-6 (This paper reviews the evidence why lipoprotein(a) (Lp(a)) is a causal risk factor for cardiovascular disease and how high Lp(a) concentrations should be managed now and with an outlook to the future.)
15.
Zurück zum Zitat Paige E, Masconi KL, Tsimikas S, Kronenberg F, Santer P, Weger S, Willeit J, Kiechl S, Willeit P. Lipoprotein(a) and incident type-2 diabetes: results from the prospective Bruneck study and a meta-analysis of published literature. Cardiovasc Diabetol. 2017;16:38.CrossRefPubMedPubMedCentral Paige E, Masconi KL, Tsimikas S, Kronenberg F, Santer P, Weger S, Willeit J, Kiechl S, Willeit P. Lipoprotein(a) and incident type-2 diabetes: results from the prospective Bruneck study and a meta-analysis of published literature. Cardiovasc Diabetol. 2017;16:38.CrossRefPubMedPubMedCentral
16.
17.
Zurück zum Zitat Langsted A, Nordestgaard BG, Kamstrup PR. Low lipoprotein(a) levels and risk of disease in a large, contemporary, general population study. Eur Heart J. 2021;42:1147–56.CrossRefPubMed Langsted A, Nordestgaard BG, Kamstrup PR. Low lipoprotein(a) levels and risk of disease in a large, contemporary, general population study. Eur Heart J. 2021;42:1147–56.CrossRefPubMed
20.
22.
Zurück zum Zitat •• Ward NC, Vickneswaran S, Watts GF. Lipoprotein (a) and diabetes mellitus: causes and consequences. Curr Opin Endocrinol Diabetes Obes. 2021 Apr 1;28(2):181–187. https://doi.org/10.1097/MED.0000000000000597. (This review provides an update on the role of lipoprotein (a) [Lp(a)] in diabetes, including its impact as a risk factor as well as its contribution to the development of cardiovascular disease.) •• Ward NC, Vickneswaran S, Watts GF. Lipoprotein (a) and diabetes mellitus: causes and consequences. Curr Opin Endocrinol Diabetes Obes. 2021 Apr 1;28(2):181–187. https://​doi.​org/​10.​1097/​MED.​0000000000000597​. (This review provides an update on the role of lipoprotein (a) [Lp(a)] in diabetes, including its impact as a risk factor as well as its contribution to the development of cardiovascular disease.)
24.
Zurück zum Zitat GholamiChahkand MS, EsmaeilpourMoallem F, Qezelgachi A, Seifouri K, PesaranAfsharian A, Sheikhzadeh F, Poursalehi A, FaniSadrabadi FS, SaghabTorbati M, Ramezanzade M, Alishiri G, Ansari A, ZareDehabadi E, KarimiMatloub S, Sheikh Z, Deravi N, Mehrtabar S, Chichagi F, FaalHamedanchi N, Arzaghi M, Asadi M, AlsadatDadkhah P, Ansari A. Lipoprotein (a) as a predictor of diabetic retinopathy in patients with type 2 diabetes: A systematic review. Diab Vasc Dis Res. 2023;20(6):14791641231197114. https://doi.org/10.1177/14791641231197114.CrossRef GholamiChahkand MS, EsmaeilpourMoallem F, Qezelgachi A, Seifouri K, PesaranAfsharian A, Sheikhzadeh F, Poursalehi A, FaniSadrabadi FS, SaghabTorbati M, Ramezanzade M, Alishiri G, Ansari A, ZareDehabadi E, KarimiMatloub S, Sheikh Z, Deravi N, Mehrtabar S, Chichagi F, FaalHamedanchi N, Arzaghi M, Asadi M, AlsadatDadkhah P, Ansari A. Lipoprotein (a) as a predictor of diabetic retinopathy in patients with type 2 diabetes: A systematic review. Diab Vasc Dis Res. 2023;20(6):14791641231197114. https://​doi.​org/​10.​1177/​1479164123119711​4.CrossRef
27.
Zurück zum Zitat Littmann K, Wodaje T, Alvarsson M, Bottai M, Eriksson M, Parini P, Brinck J. The Association of Lipoprotein(a) Plasma Levels With Prevalence of Cardiovascular Disease and Metabolic Control Status in Patients With Type 1 Diabetes. Diabetes Care. 2020;43(8):1851–8. https://doi.org/10.2337/dc19-1398.CrossRefPubMed Littmann K, Wodaje T, Alvarsson M, Bottai M, Eriksson M, Parini P, Brinck J. The Association of Lipoprotein(a) Plasma Levels With Prevalence of Cardiovascular Disease and Metabolic Control Status in Patients With Type 1 Diabetes. Diabetes Care. 2020;43(8):1851–8. https://​doi.​org/​10.​2337/​dc19-1398.CrossRefPubMed
28.
Zurück zum Zitat • Thau H, Neuber S, Emmert MY, Nazari-Shafti TZ. Targeting Lipoprotein(a): Can RNA Therapeutics Provide the Next Step in the Prevention of Cardiovascular Disease? Cardiol Ther. 2024 Mar;13(1):39–67. https://doi.org/10.1007/s40119-024-00353-w. (This comprehensive review, provide a detailed overview of RNA-based therapeutic approaches and discuss the recent advances and challenges of RNA therapeutics specifically designed to reduce Lp(a) levels and thus the risk of cardiovascular disease.) • Thau H, Neuber S, Emmert MY, Nazari-Shafti TZ. Targeting Lipoprotein(a): Can RNA Therapeutics Provide the Next Step in the Prevention of Cardiovascular Disease? Cardiol Ther. 2024 Mar;13(1):39–67. https://​doi.​org/​10.​1007/​s40119-024-00353-w. (This comprehensive review, provide a detailed overview of RNA-based therapeutic approaches and discuss the recent advances and challenges of RNA therapeutics specifically designed to reduce Lp(a) levels and thus the risk of cardiovascular disease.)
Metadaten
Titel
Exploring the Interplay between Diabetes and Lp(a): Implications for Cardiovascular Risk
verfasst von
Corral Pablo
Arrupe Matías
Augusto Lavalle Cobo
Gimenez Sergio
Renna Nicolás Federico
Publikationsdatum
28.05.2024
Verlag
Springer US
Erschienen in
Current Diabetes Reports / Ausgabe 7/2024
Print ISSN: 1534-4827
Elektronische ISSN: 1539-0829
DOI
https://doi.org/10.1007/s11892-024-01543-5

Kompaktes Leitlinien-Wissen Innere Medizin (Link öffnet in neuem Fenster)

Mit medbee Pocketcards schnell und sicher entscheiden.
Leitlinien-Wissen kostenlos und immer griffbereit auf ihrem Desktop, Handy oder Tablet.

Neu im Fachgebiet Innere Medizin

Vorhofflimmern: Antikoagulation vor Schlaganfall von Vorteil

Erleiden Menschen mit Vorhofflimmern einen ischämischen Schlaganfall, ist dieser weniger schwer, auch sind Infarktgröße und Blutungsrisiko geringer, wenn sie zuvor orale Antikoagulanzien erhalten haben. Die Art der Antikoagulation spielt dabei keine Rolle.

Frühe CLL-Therapie: BTK-Hemmer verlängert EFS und PFS, aber nicht OS

Auch nach sechs Jahren ergibt sich kein Überlebensvorteil einer Therapie mit dem BTK-Hemmer Ibrutinib für Menschen mit frühem CLL-Stadium und erhöhtem Progressionsrisiko. Die Progressionsrate wird mit der Behandlung jedoch um über 80% gesenkt.

Mehr Cholesterin im Essen = höheres Herzinfarktrisiko

Je mehr Cholesterin man täglich über die Nahrung zu sich nimmt, desto höher ist offenbar das Herzinfarktrisiko – das legt eine Studie mit US-Veteranen zumindest für Männer nahe.

Antikoagulation bei Vorhofflimmern: Sind DOAK noch zu toppen?

Gegen Thromboembolien so wirksam wie ein DOAK, bei zugleich geringerem Blutungsrisiko – werden Faktor-XI-Hemmer als neue Antikoagulanzien dieser Erwartung gerecht? Eine aktuell publizierte Vergleichsstudie gibt darüber Aufschluss.

EKG Essentials: EKG befunden mit System (Link öffnet in neuem Fenster)

In diesem CME-Kurs können Sie Ihr Wissen zur EKG-Befundung anhand von zwölf Video-Tutorials auffrischen und 10 CME-Punkte sammeln.
Praxisnah, relevant und mit vielen Tipps & Tricks vom Profi.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.